EP0746209A1 - Improving growth and lactation of ruminants - Google Patents
Improving growth and lactation of ruminantsInfo
- Publication number
- EP0746209A1 EP0746209A1 EP95911864A EP95911864A EP0746209A1 EP 0746209 A1 EP0746209 A1 EP 0746209A1 EP 95911864 A EP95911864 A EP 95911864A EP 95911864 A EP95911864 A EP 95911864A EP 0746209 A1 EP0746209 A1 EP 0746209A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- carnitine
- camitine
- increase
- milk
- feed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000282849 Ruminantia Species 0.000 title claims abstract description 28
- 230000006651 lactation Effects 0.000 title description 17
- 238000000034 method Methods 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 238000009472 formulation Methods 0.000 claims abstract description 7
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical group C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 90
- 241000283690 Bos taurus Species 0.000 claims description 36
- 239000008267 milk Substances 0.000 claims description 34
- 235000013336 milk Nutrition 0.000 claims description 33
- 210000004080 milk Anatomy 0.000 claims description 33
- 235000013365 dairy product Nutrition 0.000 claims description 12
- 235000015278 beef Nutrition 0.000 claims description 8
- 235000013325 dietary fiber Nutrition 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000004459 forage Substances 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 241000283707 Capra Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 36
- 229960004203 carnitine Drugs 0.000 abstract description 8
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 abstract 2
- 238000011282 treatment Methods 0.000 description 62
- 235000005911 diet Nutrition 0.000 description 37
- 210000003165 abomasum Anatomy 0.000 description 32
- 230000037213 diet Effects 0.000 description 31
- 244000309465 heifer Species 0.000 description 26
- 210000004767 rumen Anatomy 0.000 description 22
- 210000002381 plasma Anatomy 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 13
- 239000012530 fluid Substances 0.000 description 11
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 150000004665 fatty acids Chemical class 0.000 description 10
- 230000009469 supplementation Effects 0.000 description 10
- 235000013339 cereals Nutrition 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- 230000007423 decrease Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 239000013589 supplement Substances 0.000 description 8
- 235000019621 digestibility Nutrition 0.000 description 7
- 238000005070 sampling Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000000378 dietary effect Effects 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 5
- 235000021050 feed intake Nutrition 0.000 description 5
- 235000021243 milk fat Nutrition 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 229940070710 valerate Drugs 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- 235000019750 Crude protein Nutrition 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 235000019764 Soybean Meal Nutrition 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000004455 soybean meal Substances 0.000 description 3
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 2
- 241001182413 Aboma Species 0.000 description 2
- 244000052363 Cynodon dactylon Species 0.000 description 2
- JHJOOSLFWRRSGU-UHFFFAOYSA-N Fenchlorphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(Cl)C=C1Cl JHJOOSLFWRRSGU-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
- 102100027441 Nucleobindin-2 Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 150000001470 diamides Chemical class 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- YNPFMWCWRVTGKJ-UHFFFAOYSA-N mianserin hydrochloride Chemical compound [H+].[Cl-].C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 YNPFMWCWRVTGKJ-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000005416 organic matter Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000005974 protein supplement Nutrition 0.000 description 2
- 229940116540 protein supplement Drugs 0.000 description 2
- 239000004460 silage Substances 0.000 description 2
- 235000000891 standard diet Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- PHIQHXFUZVPYII-LURJTMIESA-O (S)-carnitinium Chemical compound C[N+](C)(C)C[C@@H](O)CC(O)=O PHIQHXFUZVPYII-LURJTMIESA-O 0.000 description 1
- OXFSTTJBVAAALW-UHFFFAOYSA-N 1,3-dihydroimidazole-2-thione Chemical compound SC1=NC=CN1 OXFSTTJBVAAALW-UHFFFAOYSA-N 0.000 description 1
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 1
- 101000599968 Bos taurus Insulin-like growth factor II Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- QZXATCCPQKOEIH-UHFFFAOYSA-N Florasulam Chemical compound N=1N2C(OC)=NC=C(F)C2=NC=1S(=O)(=O)NC1=C(F)C=CC=C1F QZXATCCPQKOEIH-UHFFFAOYSA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 235000020899 Hay diet Nutrition 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- SYHGEUNFJIGTRX-UHFFFAOYSA-N methylenedioxypyrovalerone Chemical compound C=1C=C2OCOC2=CC=1C(=O)C(CCC)N1CCCC1 SYHGEUNFJIGTRX-UHFFFAOYSA-N 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000014075 nitrogen utilization Effects 0.000 description 1
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- BJNLLBUOHPVGFT-QRZIFLFXSA-N teichomycin Chemical compound CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)OC=2C(=CC(=CC=2)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@H]2C(N[C@H](C3=CC(O)=CC(O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C3C=3C(O)=CC=C(C=3)[C@@H](NC3=O)C(=O)N2)C(O)=O)=O)Cl)=C(OC=2C(=CC(C[C@H](C(N4)=O)NC(=O)[C@H](N)C=5C=C(O6)C(O)=CC=5)=CC=2)Cl)C=C1[C@H]3NC(=O)[C@@H]4C1=CC6=CC(O)=C1 BJNLLBUOHPVGFT-QRZIFLFXSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
Definitions
- the present invention is in the general field of nutrition for ruminant animals, such as cattle and sheep.
- it relates to a method of feeding or infusing ruminant animals with a formulation which enhances the growth of the animals and/or improves the content of the milk produced by lactating animals, as evidenced, for example, by an increase in the solid-not-fat (SNF) component of the milk.
- Ruminant animal diets or infusions of this invention include an amount of a camitine, such as L- carnitine or a L-carnitine salt. The amount present in the diet or infusion is such that the growth of the animal is increased and/or the content of particular desirable components of the milk produced by lactating animals is improved over those animals not fed this diet or receiving the infusion.
- camitine stimulates the ketogenesis of palmitate in ovine hepatocytes (Faulkner et al. Comp Biochem Physiol [BJ 9S(2-3):283-6, 1991) and increased hepatic oxidation in bovine liver (Drackley et al. J Dairy Sci 74(9):3014-24, 1991). The presence of propionate blocked both of these effects. Both of these studies were done on a cellular level, and involved the addition of camitine and propionate in vitro. Camitine has been used as a feed additive for starter pigs (Blum et al. , U.S.
- Patent No. 5,192,804 for finishing pigs in combination with lysine (Blum et al. , U.S. Patent No. 5,124,357), for poultry (Blum et al. , U.S. Patent Application 08/049,258), for catfish (Blum et al. , U.S. Patent No. 5,030,657) and for domesticated dogs and cats (Keene et al., U.S. Patent No. 4,883,672).
- JP 0126420 teaches the addition of camitine for animals and humansas a growth stimulator.
- Tables 1 and 2 summarize a number of patents related to methods, generally feed additives, which increase growth rate and/or increase in lactation of rumi ⁇ nants. However, none of these methods involve the use of camitine.
- one aspect of the present invention is a diet for mminants which comprises an effective amount of camitine, where the desired effect is an increase growth rate and/or a desirable alteration in the content of milk produced by lactating ruminants.
- a further aspect of the present invention is a method of increasing growth rate of mminants which involves feeding the mminants a standard diet which has been supplemented with an effective amount of camitine. This method can also be achieved by infusion of the camitine directly into the absomassum of the animal.
- a still further aspect of the present invention is a method of altering the content of milk produced by lactating mminants which involves feeding the ruminants a standard diet which has been supplemented with an effective amount of camitine. As above, this method can also be achieved by infusion of the camitine directly into the absomassum of the animal.
- camitine supplementation increases average daily gain, indicating an increase in growth rate.
- SNF supplementation has been found to increase SNF content, which is potentially important with more markets moving to pricing milk on the basis of SNF or protein.
- the present invention relates to a diet or infusion for mminants which comprises camitine.
- the camitine is present in concentrations which make the diet or infusion suitable for use in the method of the present invention.
- the present method increases growth rate, as indicated by an increase in ADG and desirably alters the content of lactating mminants treated by this method, as indicated by increased SNF content of the milk produced.
- Camitine has also been shown to increase mtrogen retention and improve digestabilities of particular components of the cow diet. Because of the increase in SNF, it would be expected that camitine will increase milk volume and/or percentage of fat or protein in the milk.
- Suitable mminants to be fed the diet of the present invention include but is not limited to beef cattle, dairy cattle, and sheep. Animals of all ages benefit from this treatment method. For example, young animals, which have undeveloped rumen, are expected to respond to a combination of camitine and a "milk replacer" diet in a very similar fashion to older animals which have the camitine infused into the abomasum. The feeding of this diet should occur from birth to 5 months of age.
- the camitine can be any isomer of camitine, preferably L-carnitine, and can be synthetic, microbial produced, or naturally occurring. Also suitable for formulation of the diet or infusion of the present invention are salts of camitine, such as acetyl camitine.
- the camitine is present in an effective amount, where the desired effect is an increase in growth rate or a desirable alteration in the content of the milk produced.
- the animal feeds most generally used in conjunction with the method of this invention are composed of various grain mixtures and/or roughage feeds such as hay, cottonseed hulls, rice hulls, silage or other high fiber feedstuff s used in various combinations commonly fed to meat, milk and/or wool-producing mminants.
- the feed should contain from 40 to 60 percent by weight of high concentrate diet, the balance of which may be roughage. A fifty-fifty mixture is preferred.
- Such diets are known to shift the mminal volatile fatty acid (NFA) profile in the direction of more propionate production and less acetate production. This may give increased utilization of enregy and therefore more milk volume.
- NFA mminal volatile fatty acid
- the feed schedule and feed rates can also be any standard schedule and rate used in the art, including feed restrictive programs.
- Increase in growth rate can be determined by an increase in daily average growth (ADG), increase in backfat or ribfat, increase in feed conversion, or any other art accepted way of measuring growth rate.
- ADG daily average growth
- increase in backfat or ribfat increase in feed conversion, or any other art accepted way of measuring growth rate.
- Milk content of crude protein and protein components, solid-not-fat, fat and fat components can be measured using standard methods well known in the art.
- the following examples are representative of the present invention but is not to be considered limiting to the scope of the invention.
- the final diets were fed at 2.5 kg (5.5 lb)/heifer daily in feed troughs in pastures for 42 d.
- Tifton 85 hay in 55-60 lb square bales was fed free-choice in hay racks.
- Hay refusals were weighed back periodically to accurately determine hay intake.
- All heifers were weighed on two consecutive days at the initiation and termination of the trial, and the mean of these respective weights were used as initial and final weights. Heifers were weighed at 21-d intervals, providing two weight periods. On d 21, heifers were rotated on replicate pastures within treatments to remove any pasture effects. On d 1 of the trial, all heifers were injected with Vitamins A and D, injected with Discovery 4L5 ® (IBR, PI3, pneumonia, leptospirosis vaccine) and injected with Tramisol ® . A free-choice trace mineral and vitamin supplement (Nitaminde ® ) was available at all times with free access to water.
- Discovery 4L5 ® IBR, PI3, pneumonia, leptospirosis vaccine
- the two-acre (.81 ha) pastures used in the trial were composed of dormant bermudagrass stubble during the November to January time frame for the experiments. Therefore, the majority, if not all, of the nutrients for the cattle in each trial were supplied by supplemental grain and hay.
- the heifers had been weaned in early September, therefore they had ample time to recover from weaning stresses and to adapt to grain/hay diets which were provided from weaning time until trials were initiated. All heifers were bom and weaned on University of Georgia Research Farms, therefore they had received similar preweaning and postweaning management. All cattle were apparently healthy when the trial was initiated.
- the hay utilized as the basic roughage in the heifer trial was from the same hay cutting of well-fertilized Tifton 85 bermudagrass forage.
- the hay averaged 13.91 % cmde protein and 90.16% dry material (DM), and had a fresh hay odor and bright green color.
- Hay DM consumption averaged 56.5% of total dry matter intake (DMI) in the Heifer Trial (Table 6).
- Treatment means differ (P ⁇ 0.06).
- b Treatment mean differ (P ⁇ 0.01).
- c Supplements fed at 5.5 lb/hd (38.5 lb/pen daily); Est. DM 90.0%.
- d Hay samples (6 samples from 5 bales; 3 sites/bale) had 90.16% DM and 12.91 % CP.
- e Treatment means differ (P ⁇ 0.12).
- f Treatment mean In the Heifer Trial (Table 6), the average daily gain (ADG) was variable between replicators and treatments, however 21-d ADG was higher (P ⁇ 0.01) for L- carnitine supplemented treatments (26% and 21 % higher for 0.6 and 1.2 g treatments) compared with controls.
- the 42-d ADG and 42-d gain/heifer were higher (P ⁇ 0.06) for L-carnitine supplemented heifers compared with controls.
- the 42-d ADG was very similar for each replication within each L-carnitine treatment, and 42-d ADG was not improved by feeding 1.2 9/hd daily compared with 0.6 g/hd daily.
- hay was provided free-choice, there were only slight differences in consumption between treatments.
- Hay was checked for consumption daily, and fresh hay was supplied in amounts estimated to be consumed in 24 h each day.
- Hay DMI tended to be lower (P > 0.10) for increasing level of L-carnitine supplementation.
- a 42-d stocker steer trial was conducted using the same diets, experimental design and treatment assignment procedures, L-carnitine treatments, hay and grain supplements and pastures as described above.
- the steers were 10 months of age when the trial began and averaged 509.3 lb initially. All of the preliminary injections and treatments described above were administered to the steers on d 1 of the trial. Initial and final weights were means of two consecutive daily full weights.
- backfat of each steer was determined by using a Renco ® electronic backfat meter.
- Example 3 Ruminal Cannulated Steer Trial Three mature ruminally cannulated steers (avg. BW 1100 lb) were fed 14.5 lb of the same hay and 11.0 lb of the same L-carnitine treatment supplements described above (control, 0.6 g, or 1.2 g of L-carnitine/hd daily).
- the average metabolic size of the three ruminally cannulated steers was approximately two times the average of the steers and heifers used in the trials described above, therefore we assumed mmen volume would be approximately twice as large for these steers as for the stocker heifers and steers. Consequently, daily grain/protein supplement and hay were doubled, and held constant, for these steers, resulting in L-carnitine intake of 0, 1.2 or 2.4 g/steer daily.
- the steers were fed appropriate L-carnitine treatments in a 3 x 3 latin square experiment, allowing each of the three steers to be on each of the L-carnitine diets. Steers were randomly assigned to treatments initially, and followed a statistically designed format for treatment rotation. Each steer was fed the appropriate diet for 10 d in each of three periods, with sample collection over a 24-h period beginning on the morning of the last day of each period. All steers were treated for internal parasite prevention (Tramisol ® ), a respiratory infection prevention (Discovery 4L5 ® ), and injected with vitamins A and D two days before the experiment began.
- Tramisol ® a respiratory infection prevention
- Discovery 4L5 ® a respiratory infection prevention
- Ruminally cannulated steers were fed L-carnitine at 0, 1.2 or 2.4 g/hd daily utilized the same hay source with grain L-carnitine protein supplement and hay intake was adjusted to provide the same proportions of hay and grain as consumed in Examples 1 and 2.
- This procedure was designed to account for differences in mminal size and BW of ruminally cannulated steers compared with younger weaned steers and heifers utilized above. This trial was designed to provide information on mminal degradation rates for L-carnitine, effects of L-carnitine supplementation on mminal VFA production which affects energy metabolism in mminants, and to observe changes in plasma camitine levels over time when relatively high levels of dietary L-carnitine were ingested.
- Plasma urea nitrogen (PUN), plasma cholesterol and plasma triglyceride concentrations averaged over 11 sampling times within 24 h are shown in Table 8 for three dietary treatments with supplemental L-carnitine. There were no differences (P > 0.20) for dietary L-carnitine treatments for PUN, cholesterol or triglycerides, however, PUN concentrations were different (P ⁇ 0.01) over time. Cholesterol and triglyceride concentrations were not affected (P > 0.10) by sampling time.
- Figure 1 shows a gradual increase in PUN concentrations after feeding for all three dietary treatments, followed by a gradual decline after 12 h with 24 h concentrations returning to those observed a 0 h, before feeding.
- Plasma cholesterol mg/dl 96.5 99.2 102.0 1.0
- Table 9 shows ruminal fluid VFA in molar percentages averaged over 6 sampling times in a 24 h period. Key sampling times of 0, 2, 4, 8, 16 and 24 h were done. Previous research with L-carnitine supplementation had shown no treatment effects when L-carnitine was fed to feedlot cattle on high concentrate diets. The VFA means (Table 8) were remarkably similar (P > 0.10) for each individual VFA assayed. Ruminal fluid pH means were unaffected (P > 0.10) by L-carnitine supplementation, however pH was affected (P ⁇ 0.06) by sampling time, with slight decreases occurring at 1 h and 6 h postfeeding. Ruminal fluid pH ranged from 6.3 to 6.6 throughout the study, well within acceptable ranges for the kind of diet being fed.
- Ruminal fluid pH b 6.41 6.41 6.38 .04 a Means based upon six samples over 24 h intervals at 3 periods in a 3 x 3 latin square experiment using 3 ruminally cannulated steers.
- b Means for pH based upon 33 samples per steer over 11 sampling times in three 24 h periods in the 3 x 3 latin square experiment using three ruminally cannulated steers.
- Figure 4 and Table 9 show concentrations of branched chain VFA isovalerate and valerate, which are often considered minor YFA for nutrition of mminants.
- Isovalerate concentration fluctuated with time, resulting in a time effect (P ⁇ 0.05), and a trend (P > 0.10) for depressed isovalerate concentrations compared with controls throughout the 24 h period.
- Valerate concentrations increased (P ⁇ 0.01) over time ( Figure 4) from 0 h to 4 h, and gradually declined from 4 h to 16 h, and then remained stable through 24 h, returning to levels observed at 0 h.
- the statistical analyses indicated treatment differences (P ⁇ 0.01) for valerate.
- Treatments were 1) control (no camitine), 2) L-carnitine dosed into the mmen, and 3) L- carnitine infused continuously into the abomasum. Measurements of digestibilities and balances of energy and nitrogen were made by total collection of feces and urine.
- Cows were fed a total mixed diet
- the ingredients of this diet are summarized Table 10 and chemical composition is summarized in Table 11.
- L-Carnitine was administered at a mean of 5.96 g/d, which is the equivalent to 227 ppm in diet dry matter, based on actual dry matter intakes.
- L-Carnitine supplementation tended to increase total tract disgestabilities of dry matter and organic matter and significantly increase energy digestibility (Tables 16 and 17). This was largely attributable to the significantly increased digestibility of total fatty acids (also reflected in increased ether extract digestibility). Ruminal L- carnitine tended to increase digestibilities of neutral detergent fiber (NDF) and cellulose. Ruminal L-carnitine also tended to increase total volatile fatty acid (VFA) concentration in the mmen, suggesting an enhancement of rumen fermentation (Table 18). L-Carnitine, especially into the mmen, tended to increase proportion of propionate and decrease proportion of acetate in ruminal contents. TABLE 18
- L-Carnitine tended to decrease concentration of nonesterified fatty acids
- Ruminal L-carnitine resulted in improvements in nitrogen retention and productive nitrogen, arising mostly from slightly improved nitrogen digestibility (Table 20).
- L-Carnitine resulted in increases in digestible and metabolizable energy from the diet, but this did not increase milk energy secretion, indicating that additional energy was directed was directed to body storage (Tables 21 and 22).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed is a method for increasing the growth rate of ruminants which comprises administering orally to the ruminant an effect amount of carnitine. Also disclosed is a feed formulation for ruminants which comprises carnitine.
Description
IMPROVING GROWTH AND LACTATION OF RUMINANTS
FIELD OF THE INVENTION
The present invention is in the general field of nutrition for ruminant animals, such as cattle and sheep. In a particular aspect, it relates to a method of feeding or infusing ruminant animals with a formulation which enhances the growth of the animals and/or improves the content of the milk produced by lactating animals, as evidenced, for example, by an increase in the solid-not-fat (SNF) component of the milk. Ruminant animal diets or infusions of this invention include an amount of a camitine, such as L- carnitine or a L-carnitine salt. The amount present in the diet or infusion is such that the growth of the animal is increased and/or the content of particular desirable components of the milk produced by lactating animals is improved over those animals not fed this diet or receiving the infusion.
BACKGROUND OF THE INVENTION
Recent studies on the function of camitine in metabolism in lactating ruminants have found that camitine stimulates the ketogenesis of palmitate in ovine hepatocytes (Faulkner et al. Comp Biochem Physiol [BJ 9S(2-3):283-6, 1991) and increased hepatic oxidation in bovine liver (Drackley et al. J Dairy Sci 74(9):3014-24, 1991). The presence of propionate blocked both of these effects. Both of these studies were done on a cellular level, and involved the addition of camitine and propionate in vitro. Camitine has been used as a feed additive for starter pigs (Blum et al. , U.S.
Patent No. 5,192,804), for finishing pigs in combination with lysine (Blum et al. , U.S. Patent No. 5,124,357), for poultry (Blum et al. , U.S. Patent Application 08/049,258), for catfish (Blum et al. , U.S. Patent No. 5,030,657) and for domesticated dogs and cats (Keene et al., U.S.
Patent No. 4,883,672). JP 0126420 teaches the addition of camitine for animals and humansas a growth stimulator. However, none of these feed are formulated for the use of ruminant animals, nor is there any suggestion that ruminants would display an increase in growth rate or an improvement in the content of milk or the components of the milk or the digestability of the feed of lactating ruminants with the feeding of ca itine. Additionally, none of these report the infusion of camitine directly into the stomach of the animal.
Tables 1 and 2 summarize a number of patents related to methods, generally feed additives, which increase growth rate and/or increase in lactation of rumi¬ nants. However, none of these methods involve the use of camitine.
TABLE 1
INCREASE GROWTH RATE
Patent No. Date Inventor Additive Purpose
5,202,136 04/13/93 Evans et al. saturated fat (at weight gain rate least 10C)
4,760,909 07/26/88 Nissen et al. ketoisocaproate increase weight gain or wool
4,353,902 10/12/82 Hedde et al. histamine H2 increase growth receptor agonist
4,258,031 03/24/81 Fletcher et ronnel/monersin increase growth al.
4,211,775 07/08/80 Ioset ronnel increase growth
4,186,212 01/29/80 Howell HMW/aliphatic increase alcohols metabolic energy
4,087,554 05/02/78 Haydock et iodonium salts increase growth al. rate/feed effciency
3,953,606 04/27/76 Demkovich uroidotetralin increase growth et al. rate
3,210,194 10/05/65 Burroughs 2- promote mercaptoimidazole/c growth/increase arotine feed utilization
2,951,759 09/06/60 DeZeiw et glucocorticoid growth stimulus al.
TABLE 2
INCREASE LACTATION
Patent No. Date Inventor Additive Purpose
5,141,922 01/29/80 Krivi val126 BGH enhance lactation
5,041,452 08/20/91 White diamides increase feed util. /lactation
4,978,682 12/18/90 White diethanolamine increase feed triacetic acid util ./lactation
4,966,917 10/30/90 White tetramide increase feed util ./lactation
4,895,951 08/20/91 White heterocyclic increase feed diamides util ./lactation
4,883,820 11/28/89 White tetramide increase feed util. /lactation
4,882,355 12/18/90 White diethanolamine increase feed triacetic acid util. /lactation triamides
4,801,618 11/28/89 White diamino tetramides increase feed util ./lactation
4,800,213 12/18/90 White diethanolamine increase feed triacetic triamides util. /lactation
4,783,524 11/08/88 Kotts et al. bovine IGF-II increase (peptides) growth/lactation
4,704,276 11/03/87 Kantor antibiotic LL- increase growth E19020 rate/feed util. /lactation
4,534,969 08/13/85 Phillips antibiotic increase lactation teichomycin
4,430,328 02/07/84 Scheifinger glycopeptide increase lactation antibiotics
4,336,250 06/22/82 Scheifinger virginiamyan/elfa increase milk mycin production
All of the patented methods involve the addition of compounds other than camitine, many of which are expensive and may have other unwanted effects on the animal. Therefore, there remains a need in the art for a method of increasing growth rate of ruminants and/or altering milk content of lactating ruminants or increasing digestability of the feed which is inexpensive and does not affect other aspects of the mminants' health. Accordingly, one aspect of the present invention is a diet for mminants which comprises an effective amount of camitine, where the desired effect is an increase growth rate and/or a desirable alteration in the content of milk produced by lactating ruminants. A further aspect of the present invention is a method of increasing growth rate of mminants which involves feeding the mminants a standard diet which has been supplemented with an effective amount of camitine. This method can also be achieved by infusion of the camitine directly into the absomassum of the animal.
A still further aspect of the present invention is a method of altering the content of milk produced by lactating mminants which involves feeding the ruminants a standard diet which has been supplemented with an effective amount of camitine. As above, this method can also be achieved by infusion of the camitine directly into the absomassum of the animal.
SUMMARY OF THE INVENTION
It has now been discovered that by feeding camitine to mminants, or infusing camitine into the abomasum, there is an increase in growth rate of the animal. Further, if the ruminant is lactating, there is a desirable alteration in the content of the milk produced. This is achieved by feeding mminants a diet which comprises an effective amount of camitine. Alternatively, the camitine can be infiised directly into the abomasum of the animal. Specifically, it has been discovered that camitine supplementation increases average daily gain, indicating an increase in growth rate. In lactating ruminants, camitine supplementation has been found to increase SNF content, which is potentially important with more markets moving to pricing milk on the basis of SNF or protein. This treatment has also been shown to change in nitrogen retention and utilization which is important for improving production efficiency, and also will become increasingly important from the standpoint of decreasing nitrogen excretion into the
environment. Finally, an improvement in digestibilities of fatty acids, fiber, energy, and crude protein by dairy cows with camitine supplementation offers potential for increasing productive efficiency.
DETAILED DESCRIPTION OF THE INVENTION All patent applications, patents, and literature references cited in this specification are hereby incorporated by reference in their entirety.
The present invention relates to a diet or infusion for mminants which comprises camitine. The camitine is present in concentrations which make the diet or infusion suitable for use in the method of the present invention. The present method increases growth rate, as indicated by an increase in ADG and desirably alters the content of lactating mminants treated by this method, as indicated by increased SNF content of the milk produced. Camitine has also been shown to increase mtrogen retention and improve digestabilities of particular components of the cow diet. Because of the increase in SNF, it would be expected that camitine will increase milk volume and/or percentage of fat or protein in the milk.
Suitable mminants to be fed the diet of the present invention include but is not limited to beef cattle, dairy cattle, and sheep. Animals of all ages benefit from this treatment method. For example, young animals, which have undeveloped rumen, are expected to respond to a combination of camitine and a "milk replacer" diet in a very similar fashion to older animals which have the camitine infused into the abomasum. The feeding of this diet should occur from birth to 5 months of age.
The camitine can be any isomer of camitine, preferably L-carnitine, and can be synthetic, microbial produced, or naturally occurring. Also suitable for formulation of the diet or infusion of the present invention are salts of camitine, such as acetyl camitine. The camitine is present in an effective amount, where the desired effect is an increase in growth rate or a desirable alteration in the content of the milk produced.
Given the detailed guidance of the present specification, it is believed within the level of one of ordinary skill to test a range of camitine concentrations using a trial feed in order to optimize the concentration for the particular species and breed being fed or infused. Table 3 lists average feed intake for various sizes and types of ruminants, to be combined with the camitine. The average daily feed intake figures are from "Clinical and Diagnostic Veterinary Toxicology, 2nd ed. , William B. Buck et al. Kendall/Hunt
Publishing Co. Dubuque, Iowa. Generally, the effective camitine concentration is between about 125 mg per head per day to about 20 grams per head per day. The preferred amount is dependent on the particular animal being treated and the size of the animal. For specific recurrent nutritional requirements, reference is made to such publications as the 1985 NRC Publication on Sheep, the 1984 Publication on Beef and the 1978 NRC Publication on Dairy Cattle (such references being incorporated by reference herein) and such similar publications as are well known in the art. In feeding or infusing dairy cattle, a preferred amount is approximately 5 grams per head per day. In feeding or infusing beef cattle, a preferred amount is approximately 2 grams per head per day.
TABLE 3
Bodv Weight
% Feed Intake lbs. kg - Body Weight
Beef Cattle
300 136 2.3
450 204 2.5
650 295 2.4
1000 454 2.1
Lactating Cattle
770 350 1.4
1760 500 1.2
Non-Lactating Dairv Cattle
770 350 1.8
1960 800 1.2
59 27 4.5
99 45 3.9
The animal feeds most generally used in conjunction with the method of this invention are composed of various grain mixtures and/or roughage feeds such as hay,
cottonseed hulls, rice hulls, silage or other high fiber feedstuff s used in various combinations commonly fed to meat, milk and/or wool-producing mminants. Generally, the feed should contain from 40 to 60 percent by weight of high concentrate diet, the balance of which may be roughage. A fifty-fifty mixture is preferred. Such diets are known to shift the mminal volatile fatty acid (NFA) profile in the direction of more propionate production and less acetate production. This may give increased utilization of enregy and therefore more milk volume.
The feed schedule and feed rates can also be any standard schedule and rate used in the art, including feed restrictive programs. Increase in growth rate can be determined by an increase in daily average growth (ADG), increase in backfat or ribfat, increase in feed conversion, or any other art accepted way of measuring growth rate.
Milk content of crude protein and protein components, solid-not-fat, fat and fat components can be measured using standard methods well known in the art. The following examples are representative of the present invention but is not to be considered limiting to the scope of the invention.
Research was conducted to determine effects of camitine supplementation of stocker heifer and steer diets consisting of good quality hay fed with a com-soybean mal supplement on pasture. Ruminally cannulated steers were fed the diets to determine NFA, and mminal fluid and plasma camitine concentrations over 24-h intervals. Finally, a trial on dairy cows was conducted to determine the effect of camitine of milk production and content, as well as the nutrition effects on the cows themselves.
Example 1: Heifer Trial Experimental Procedure:
Forty-two (42) beef heifers, approximately 9 months of age (473.4 lb average initial weight) were assigned by breed and weight to six groups of seven heifers. Two groups of heifers were then randomly assigned to each of three L-carnitine treatments: A=No L-carnitine; B=0.6 g L-carnitine/hd daily; C = 1.2 g L-carnitine/hd daily (Table 4). The L-carnitine premixes (Treatments B and C) were added at 1.0% (20 lb/ton) of final diet composed of 75 % ground com and 25 % soybean meal (Table 5). The final diets were fed at 2.5 kg (5.5 lb)/heifer daily in feed troughs in pastures for 42 d. Tifton 85 hay in 55-60 lb square bales was fed free-choice in hay racks. Hay refusals were weighed back periodically to accurately determine hay intake.
TABLE 4
EXPERIMENTAL PADDOCKS AND DESIGN OF HEIFER AND STEER TRIALS
L-Carnitine, g/hd daily
Item
0 0.6 1.2
Heifer trial
No. pastures (0.81 ha) 2 2 2 No. heifers 14 14 14 Initial wt. lb. 472 475 474
Steer trial
No. pastures (0.81 ha) 2 2 2 No. steers 14 14 14 Initial wt. lb. 508 510 510
TABLE 5 PREMIX AND FINAL DIET COMPOSITION
Premix formulation
Item
Premix Aa Premix B Premix C
Ground corn, kg(lb) 0 35.409 (78.077) 34.537 (76.154)
L-Carnitine, kg(lb) 0 .872 (1.923) 1.744 (3.846) g/lb 0 10.9 21.8
Total 80.0 80.0
L-Carnitine g/hd/dayb
Final treatment supplement: (A) 0 (b)0.6 (C) 1.2
Com 1500 1480 1480
Soybean meal 500 500 500
Premix (A, B, or C), lb 0 20 20 No premix A was formulated - 0 camitine. b Treatment supplements containing premix A, B, or C fed at 5.5 lb (2.5 kg) per heifer (38.5 lb/day for each pen of 7 heifers) to deliver 0, .6 or 1.2 g carnitine/hd daily. Hay fed free- choice.
All heifers were weighed on two consecutive days at the initiation and termination of the trial, and the mean of these respective weights were used as initial and final weights. Heifers were weighed at 21-d intervals, providing two weight periods. On d 21, heifers were rotated on replicate pastures within treatments to remove any pasture effects. On d 1 of the trial, all heifers were injected with Vitamins A and D, injected with Discovery 4L5® (IBR, PI3, pneumonia, leptospirosis vaccine) and injected with Tramisol®. A free-choice trace mineral and vitamin supplement (Nitaminde®) was available at all times with free access to water.
The two-acre (.81 ha) pastures used in the trial (Table 4) were composed of dormant bermudagrass stubble during the November to January time frame for the experiments. Therefore, the majority, if not all, of the nutrients for the cattle in each trial were supplied by supplemental grain and hay. The heifers had been weaned in early September, therefore they had ample time to recover from weaning stresses and to adapt to grain/hay diets which were provided from weaning time until trials were initiated. All
heifers were bom and weaned on University of Georgia Research Farms, therefore they had received similar preweaning and postweaning management. All cattle were apparently healthy when the trial was initiated.
The hay utilized as the basic roughage in the heifer trial was from the same hay cutting of well-fertilized Tifton 85 bermudagrass forage. The hay averaged 13.91 % cmde protein and 90.16% dry material (DM), and had a fresh hay odor and bright green color. Hay DM consumption averaged 56.5% of total dry matter intake (DMI) in the Heifer Trial (Table 6).
TABLE 6
PERFORMANCE OF WEANED HEIFERS FED L-CARNITINE AND HAY DIETS
Item Control 0.6g L- 1.2g L- SE
Xf Carnitine X Carnitine X
R. R2 R. R2 R. R2
No. 7 7 7 7 7 7
In. wt. lb 473 471 472 476 473 475 472 475 474 12.
2
Day 21 wt 483 474 479 507 496 501 489 495 492 12. 3
Gain (42-d), lba 50 40 45 57 56 56 55 55 55 3.5
ADG lb Day 21b 0.48 0.19 0.34 1.40 1.07 1.27 0.82 0.94 0.88 0.1 Day 42c 1.19 0.96 1.07 1.36 1.34 1.35 1.30 1.31 1.30 4 0.0
8
Feed intake, lb
Supplement 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5
Suppl. DMC 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0
Hay, as-fed 7.6 7.0 7.3 7.0 7.5 7.2 7.4 6.9 7.1
Hay DMId 6.8 6.3 6.6 6.3 6.7 6.5 6.7 6.2 6.4
Total DMI 11.8 11.3 11.6 11.3 11.7 11.5 11.7 11.2 11.4
DMI 42d 496 475 487 475 491 483 491 470 479
Feed/gain (DM)e 9.9 11.9 10.9 8.3 8.8 8.6 8.9 8.5 8.7 0.6
Treatment means differ (P < 0.06). b Treatment mean differ (P< 0.01). c Supplements fed at 5.5 lb/hd (38.5 lb/pen daily); Est. DM=90.0%. d Hay samples (6 samples from 5 bales; 3 sites/bale) had 90.16% DM and 12.91 % CP. e Treatment means differ (P< 0.12). f Treatment mean
In the Heifer Trial (Table 6), the average daily gain (ADG) was variable between replicators and treatments, however 21-d ADG was higher (P < 0.01) for L- carnitine supplemented treatments (26% and 21 % higher for 0.6 and 1.2 g treatments) compared with controls. The 42-d ADG and 42-d gain/heifer were higher (P < 0.06) for L-carnitine supplemented heifers compared with controls. The 42-d ADG was very similar for each replication within each L-carnitine treatment, and 42-d ADG was not improved by feeding 1.2 9/hd daily compared with 0.6 g/hd daily. Although hay was provided free-choice, there were only slight differences in consumption between treatments. Hay was checked for consumption daily, and fresh hay was supplied in amounts estimated to be consumed in 24 h each day. Hay DMI tended to be lower (P > 0.10) for increasing level of L-carnitine supplementation. With increased gain on L- carnitine treatments and similar DMI intake for all treatments, feed conversion efficiency was improved (P < 0.12) by 26.7% and 25.3%, respectively, for 0.6 g and 1.2 g L- carnitine treatments compared with controls.
Example 2: Steer Trial
A 42-d stocker steer trial was conducted using the same diets, experimental design and treatment assignment procedures, L-carnitine treatments, hay and grain supplements and pastures as described above. The steers were 10 months of age when the trial began and averaged 509.3 lb initially. All of the preliminary injections and treatments described above were administered to the steers on d 1 of the trial. Initial and final weights were means of two consecutive daily full weights. On d 42 of the steer trial, backfat of each steer was determined by using a Renco® electronic backfat meter.
As above, the steers have been weaned in early September. All steers were born and weaned on University of Georgia Research Farm. All were apparently healthy when the trial was initiated. The same cutting of hay was used as above. Hay DM consumption averaged 65.2% of the total DMI in the Steer Trial.
In this trial (Table 7), the control steers actually gained slightly more than L-carnitine treatment steers at both d 21 and for the entire 42-d trial. There were no significant differences (P < 0.10) for any treatments in this experiment. The replication 2 steers in each of the L-carnitine treatments tended to have lower gains than replication
1 steers and control steers. Reasons for those differences in performance are not currently known.
TABLE 7
The hay intake was higher for steers than for heifers (Tables 6 and 7), primarily because of colder weather later in the season during the Steer trial, and because the BW was greater initially for the steers. Differences in hay consumption (Table 7) among treatments were minimal. Food/gain ratios were lowest for controls, and 15.1 %
and 13.1 % higher (P < 0.20), respectively, for 0.6 g and 1.2 g L-carnitine treatments compared with controls.
Individual steer backfat depth at the initiation of the trial (d 1) and at d 42 (Table 7) were measured. Treatment means indicated that all steers increased backfat depth during the 42-d trial. Steers fed 0.6 g of L-carnitine apparently had the highest increase in level of backfat, followed by control steers, with the high-level L-carnitine steers (1.2 g/hd daily) posting the smallest amount of change. Variation was quite high for backfat measurements, consequently there were no treatment differences (P > 0.20). It should be noted that one replication of the 1.2 g L-carnitine treatment had a 2.3 mm increase in backfat compared with a 0.1 mm decline in backfat for the other replication. The highest numerical changes in backfat depth were measured for steers on the two L- carnitine treatments.
Example 3: Ruminal Cannulated Steer Trial Three mature ruminally cannulated steers (avg. BW 1100 lb) were fed 14.5 lb of the same hay and 11.0 lb of the same L-carnitine treatment supplements described above (control, 0.6 g, or 1.2 g of L-carnitine/hd daily). The average metabolic size of the three ruminally cannulated steers was approximately two times the average of the steers and heifers used in the trials described above, therefore we assumed mmen volume would be approximately twice as large for these steers as for the stocker heifers and steers. Consequently, daily grain/protein supplement and hay were doubled, and held constant, for these steers, resulting in L-carnitine intake of 0, 1.2 or 2.4 g/steer daily.
The steers were fed appropriate L-carnitine treatments in a 3 x 3 latin square experiment, allowing each of the three steers to be on each of the L-carnitine diets. Steers were randomly assigned to treatments initially, and followed a statistically designed format for treatment rotation. Each steer was fed the appropriate diet for 10 d in each of three periods, with sample collection over a 24-h period beginning on the morning of the last day of each period. All steers were treated for internal parasite prevention (Tramisol®), a respiratory infection prevention (Discovery 4L5®), and injected with vitamins A and D two days before the experiment began.
On d 10 of each period, samples were collected beginning at 0700 h, and steers were then immediately fed daily grain/L-carnitine supplements and hay Jugular
blood and mminal fluid samples were obtained at 0 h before feeding and at 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24 postfeeding. Ruminal fluid was strained through 6 layers of cheesecloth and pH was immediately determined. Blood samples were processed yielding plasma for plasma urea nitrogen, plasma cholesterol, plasma triglyceride and plasma camitine analyses. Ruminal fluid samples were treated with perchloric acid (1.5 ml/dl of whole ruminal fluid) to stop microbial activity, and then centrifuged (10,000 RPM) to remove larger particles before freezing. Ruminal fluid samples were subjected to analyses to determine VFA and camitine concentrations.
Appropriate statistical analyses were performed on data from each of the three trials in cooperation with our staff statistical consultant in the Department of Computer and Statistical Services, CPES, Tifton.
Ruminally cannulated steers were fed L-carnitine at 0, 1.2 or 2.4 g/hd daily utilized the same hay source with grain L-carnitine protein supplement and hay intake was adjusted to provide the same proportions of hay and grain as consumed in Examples 1 and 2. This procedure was designed to account for differences in mminal size and BW of ruminally cannulated steers compared with younger weaned steers and heifers utilized above. This trial was designed to provide information on mminal degradation rates for L-carnitine, effects of L-carnitine supplementation on mminal VFA production which affects energy metabolism in mminants, and to observe changes in plasma camitine levels over time when relatively high levels of dietary L-carnitine were ingested.
Plasma urea nitrogen (PUN), plasma cholesterol and plasma triglyceride concentrations averaged over 11 sampling times within 24 h are shown in Table 8 for three dietary treatments with supplemental L-carnitine. There were no differences (P > 0.20) for dietary L-carnitine treatments for PUN, cholesterol or triglycerides, however, PUN concentrations were different (P < 0.01) over time. Cholesterol and triglyceride concentrations were not affected (P > 0.10) by sampling time. Figure 1 shows a gradual increase in PUN concentrations after feeding for all three dietary treatments, followed by a gradual decline after 12 h with 24 h concentrations returning to those observed a 0 h, before feeding. These results suggest that L-carnitine supplementation at high levels on a relatively high roughage diet has very little, if any effect on nitrogen uptake from the rumen.
TABLE 8
PLASMA UREA NITROGEN. PLASMA CHOLESTEROL AND PLASMA TRIGLYCERIDE VALUES FOR STEERS FED THREE L-CARNITINE LEVELS OVER TIME
Item Added dietary L-carnitine (g/d)
0 1.2 g 2.4 g SE
No. observations3 33 33 33
PUN, mg/dl 19.6 19.2 19.6 0.6
Plasma cholesterol, mg/dl 96.5 99.2 102.0 1.0
Plasma triglyceride mg/dl 22.1 22.1 22.8 0.6 a Mean of data collected at 11 times during a 24 h period in a 3 x 3 latin square using 3 ruminally cannulated steers.
Table 9 shows ruminal fluid VFA in molar percentages averaged over 6 sampling times in a 24 h period. Key sampling times of 0, 2, 4, 8, 16 and 24 h were done. Previous research with L-carnitine supplementation had shown no treatment effects when L-carnitine was fed to feedlot cattle on high concentrate diets. The VFA means (Table 8) were remarkably similar (P > 0.10) for each individual VFA assayed. Ruminal fluid pH means were unaffected (P > 0.10) by L-carnitine supplementation, however pH was affected (P < 0.06) by sampling time, with slight decreases occurring at 1 h and 6 h postfeeding. Ruminal fluid pH ranged from 6.3 to 6.6 throughout the study, well within acceptable ranges for the kind of diet being fed.
TABLE 9
RUMINAL FLUID VOLATILE FATTY ACIDS (VFA) AND
PH MEASURED OVER TIME IN
STEERS FED THREE LEVELS OF L-CARNITINE
Item Added dietary L-carnitine (g/d)
0 1.2 2.4 SE
No. observations3 18 18 18
VFA, mol/100 mol
Acetic 67.0 67.2 67.5 .32
Propionic 17.2 17.5 17.0 .8
Isobutyric 1.6 1.5 1.6 .1
Butyric 11.0 10.7 10.8 .5
Isovaleric 2.1 2.0 2.0 .03
Valeric 1.1 1.1 1.1 .01
Acetate/propionate 3.9 3.9 4.0 .2
Total VFA, μM/liter 93.1 92.6 94.4 1.2
Ruminal fluid pHb 6.41 6.41 6.38 .04 a Means based upon six samples over 24 h intervals at 3 periods in a 3 x 3 latin square experiment using 3 ruminally cannulated steers. b Means for pH based upon 33 samples per steer over 11 sampling times in three 24 h periods in the 3 x 3 latin square experiment using three ruminally cannulated steers.
The changes in VFA concentrations with time are shown in Figures 2, 3 and
4. There were no treatment effects for acetate and propionate over a 24 h period (Table 9), but acetate and propionate concentrations were affected (P < 0.05) by time of sampling. In Figure 2, ruminal acetate tended to decrease between 2 h and 16 h postfeeding, with a sharp increase between 16 b and 24 h. Corresponding increases in propionate concentrations were observed when acetate concentrations declined, and propionate declined slightly after 16 h when acetate increased. These trends in acetate and propionate concentrations may be explained by digestion of grain portion of the diet during the interval from 2 h to 16 hr, which probably contributed to the classic shifts in acetate and propionate concentrations. Although not statistically significant, propionate
concentrations were lower on the L-carnitine treatments from 4 h to 16 h postfeeding compared with the controls. The acetate: propionate ratios were affected (P < 0.05) by time, but the means over the 24 h period were not affected by treatment (Table 9).
In Figure 3, isobutyrate was unaffected by time or treatment (data at bottom of Figure 3). Butyrate concentrations (Figure 3, Top), were affected (P < 0.01) by time, but not by treatment (P > 0.10). Butyrate concentrations for all treatments tended to increase after feeding at 0 h, and remained slightly elevated until 16 h postfeeding, when all treatments declined to approximately the same concentrations at 24 h as the initial concentrations at 0 h. Significance of these changes is unknown, especially since plasma triglycerides were unaffected by time or treatment.
Figure 4 and Table 9 show concentrations of branched chain VFA isovalerate and valerate, which are often considered minor YFA for nutrition of mminants. Isovalerate concentration fluctuated with time, resulting in a time effect (P < 0.05), and a trend (P > 0.10) for depressed isovalerate concentrations compared with controls throughout the 24 h period. Valerate concentrations increased (P < 0.01) over time (Figure 4) from 0 h to 4 h, and gradually declined from 4 h to 16 h, and then remained stable through 24 h, returning to levels observed at 0 h. The statistical analyses indicated treatment differences (P < 0.01) for valerate.
Example 4: Dairy Cows Trial
Experimental Procedure:
This trial was a replicated 3 x 3 latin square design using 6 multiparous
Holstein cows that averaged 51 days into lactation at the start of the experiment.
Therefore, there were 6 observations per treatment for all variables. Periods were 21 days long, with the first 14 days for adaptation and the last 7 for data collection.
Treatments were 1) control (no camitine), 2) L-carnitine dosed into the mmen, and 3) L- carnitine infused continuously into the abomasum. Measurements of digestibilities and balances of energy and nitrogen were made by total collection of feces and urine.
Cows were fed a total mixed diet The ingredients of this diet are summarized Table 10 and chemical composition is summarized in Table 11. L-Carnitine was administered at a mean of 5.96 g/d, which is the equivalent to 227 ppm in diet dry matter, based on actual dry matter intakes.
TABLE 10 INGREDIENT COMPOSITION OF TOTAL MIXED DIET
Ingredient % of DM
Alfalfa haylage 30.00
Com silage 20.00
Soyhulls, pelleted 4.00
Soybean meal 14.00
Com, ground shelled 25.90
Energy Booster 3.00
Sodium bicarbonate 0.75
Magnesium oxide 0.15
Dicalcium phosphate 1.00
Limestone 0.85
Sodium chloride 0.20
DI Dairy Min/Vit 0.15
TABLE 11 CHEMICAL COMPOSITION OF TOTAL MIXED DIET
^McaϊTkg
The experimental design was balanced with respect to carry-over effects, and all variables were tested statistically for presence of significant carry-over affects.
If carry-over effects were detected, direct-effect means were calculated, which in effect are means "adjusted" to remove the carry-over affects.
Statistical contrasts used were 1) control vs. L-carnitine treatments, and 2) ruminally delivered L-carnitine vs. abomasally infused L-carnitine. As seen in Table 12, feed intake and milk production were not affected significantly by L-carnitine. However, the content of solids - not-fat (SNF) in milk was increased by either ruminal or abomasal L-carnitine (see, line 6). Because milk protein fractions were not altered significantly by L-carnitine (Table 13), the increase in SNF may be attributable to increased lactose content (which was not measured directly). Abomasally infused L-carnitine tended to decrease milk fat content and decreased milk fat yield. The fatty acid composition of milk fat was not altered appreciably by L-carnitine (Tables 14 and 15).
TABLE 12 EFFECT OF ADMINISTRATION OF L-CARNITINE INTO THE RUMAN OR ABOMASUM ON DMI.
MILK YIELD AND MILK COMPOSITION
Treatments Contrast (P)
Item Control Ruman Abonasu SEM Control vs. Ruman vs. L-Carnitine Abomasu m
DMI, kg/d1 26.3 26.3 26.0 0.59 0.89 0.79
Milk, kg/d 41.6 42.2 41.0 0.68 0.99 0.26
3.5% FCM, kg/d 42.2 43.1 40.8 0.41 0.64 0.01
CP, %2 3.09 3.08 3.08 0.02 0.57 0.84
CP, kg/d 1.29 1.30 1.27 0.02 0.96 0.35
SNF, % 7.94 8.16 8.09 0.05 0.02 0.34
SNF, kg/d 3.31 3.45 3.32 0.07 0.41 0.25
Fat, % 3.59 3.64 3.47 0.06 0.52 0.51
Fat, kg/d 1.49 1.63 1.42 0.01 0.41 0.002
'Carryover effect />= 0.095 Direct effect means 26.0 25.2 27.3 0.76 0.08
Carryover effect p= 0.042 Direct effect means 3.05 3.05 3.14 0.19 0.04
TABLE 13
EFFECT OF ADMINISTRATION OF L-CARNITINE INTO THE
RUMEN OR ABOMASUM ON N COMPONENTS OF MILK
Item Treatments SEM Contrast (P)
Control Rumen Abomasum Control Rumen vs. vs. Camitine Abomasu m
Total N
%' 0.485 0.482 0.483 0.003 0.57 0.84 g/d 201.8 203.8 198.7 3.6 0.89 0.35
True N
%2 0.451 0.450 0.450 0.003 0.63 0.89 g/d 188.0 190.0 185.0 3.3 0.92 0.33
% of total N 93.16 93.21 93.20 .08 0.67 0.95
Casein N
% 0.353 0.353 0.349 0.002 0.33 0.15 g/d 147.2 1491 143.4 2.1 0.73 0.10
% of total N 72.98 73.34 72.23 0.42 0.72 0.11 as % of true N 78.34 78.71 77.51 0.46 0.69 0.12
Whey N
% 0.099 0.096 0.101 0.002 0.80 0.21 g/d 40.8 40.9 41.7 1.4 0.79 0.69
% of total N 20.18 19.86 20.96 0.43 0.67 0.12 as % of true N 21.66 21.30 22.49 0.46 0.69 0.12
NPN
% 0.0332 0.0327 0.0329 0.0004 0.37 0.66 g/d 13.9 13.9 13.6 0.30 0.66 0.65
% of total N 5.84 5.80 6.80 0.08 0.67 0.95
'Carryover p= .04l effect .479 .475 .490 0.19 0.04
Direct effect means Caπyover p= .019 effect .446 .445 .460 0.13 0.02
Direct effect means
TABLE 14
COMPOSITION OF MILK FAT FROM COWS ADMINSTERED WITH L-CARNITINE INTO THE RUMEN OR ABOMASUM
Item Treatments SEM Contrast (P)
Control Rumen Abomasum Control Rumen vs. vs. Abomasum Camitine
4:0 2.0 1.8 2.0 0.1 0.89 0.26
6:0 2.2 2.0 2.1 0.04 0.02 0.02
8:0 1.3 1.1 1.2 0.04 0.16 0.38
10:0 3.0 2.9 3.0 0.1 0.65 0.75
12:0 3.6 3.6 3.6 0.2 0.89 0.98
14:0 10.6 10.6 10.6 0.3 0.96 0.98
14:1 1.2 1.2 1.2 0.02 0.36 0.85
15:0 1.2 1.2 1.2 0.1 0.51 0.80
16:0 28.4 28.6 29.1 0.2 0.10 0.12
16:1 1.6 1.7 1.6 0.04 0.03 0.19
17:0 0.7 0.7 0.7 0.01 0.43 0.68
18:0 8.5 8.0 8.3 0.3 0.28 0.41
18: 1 20.6 21.2 20.0 0.6 0.96 0.26
18:2 2.8 2.8 2.7 0.1 0.57 0.24
18:3 0.5 0.7 0.5 0.2 0.56 0.38
Glycerol 12.1 12.1 12.1 0.03 0.29 0.36
TABLE 15
PRODUCTION OF FATTY ACIDS AND GYCEROL
IN MILK FAT OF COWS
ADMINSTERED WITH L-CARNITINE INTO THE RUMEN OR ABOMASUM
Fatty Acids Treatments SEM Contrast (P)
Control Rumen Abomasum Control Rumen vs. vs. Abomasum Camitine (g/d)
4:0 29.4 28.7 28.7 1.3 0.67 0.98
6:0 32.9 29.9 30.2 0.6 0.006 0.76
8:0 18.6 17.3 17.0 0.6 0.09 0.71
10:0 44.8 44.3 42.5 1.8 0.53 0.51
12:0 53.8 54.5 51.6 2.5 0.92 0.44
14:0 157.0 161.0 151.7 4.3 0.91 0.17
14: 1 17.5 17.4 16.5 0.4 0.37 0.19
15:0 17.5 18.6 18.1 1.0 0.51 0.72
16:0 421.9 437.1 415.5 5.8 0.65 0.04
16:1 22.0 25.5 22.6 0.7 0.06 0.03
17:0 10.0 10.5 9.7 0.2 0.73 0.04
18:0 129.2 123.5 117.6 4.0 0.13 0.33
18: 1 308.9 326.4 285.1 11.8 0.83 0.05
18:2 41.0 42.6 38.4 0.5 0.40 0.0006
18:3 7.9 11.2 7.8 2.2 0.58 0.31
Glycerol 181.1 184.9 172.4 1.4 0.20 0.0007
TABLE 16
APPARENT NUTRIENT DIGESTIBILITIES FOR COWS
ADMINISTERED WITH L-CARNITINE INTO
THE RUMEN OR ABOMASUM
Item Treatments SEM Contrast (P)
Control Rumen Abomasum Control Rumen vs. vs. Abomasum Camitine (%)
Dry Matter 63.4 65.6 64.5 0.8 0.13 0.34
Crude protein 63.4 66.6 64.5 1.1 0.18 0.26
Ether extract 74.4 78.7 79.3 1.0 0.008 0.70
NDF 34.0 38.4 34.6 1.8 0.29 0.19
NDF 44.0 46.9 44.1 1.2 0.36 0.15
Hemicellulose 56.0 57.2 55.5 1.0 0.83 0.29
Cellulose 48.5 50.6 48.6 0.9 0.38 0.19
Ash 46.5 51.4 46.4 2.9 0.52 0.26
Energy 61.9 64.1 63.3 0.5 0.03 0.33
Organic matter 65.2 67.1 66.3 0.6 0.08 0.41
Soluble residue 66.6 68.1 68.3 0.9 0.26 0.89
TABLE 17
APPARENT DIGESTIBILITIES OF FATTY ACIDS
FOR COWS ADMINISTERED WITH L-CARNITINE
INTO THE RUMEN OR ABOMASUM
Treatments SEM Contrast (P)
Fatty Acids
Control Rumen Abomasum Control vs. Rumen vs. L-carnitine Abomasum
12:0 89.1 89.1 89.9 0.8 0.53 0.35
14:0 49.0 51.8 49.3 1.05 0.28 0.14
16:0 56.4 58.9 58.7 0.7 0.04 0.82
10:0 5.0 9.1 13.3 3.5 0.27 0.42
18:1 83.3 84.4 84.4 0.3 0.05 0.91
18:2 91.4 92.0 92.8 0.4 0.09 0.20
18:3 96.8 97.1 0.1 0.09 0.66
Total 18 58.1 60.3 61.6 1.2 0.10 0.49
Total 16 57.2 59.7 59.4 0.7 0.04 0.77
Total 68.9 61.3 61.3 0.8 0.05 0.98
L-Carnitine supplementation tended to increase total tract disgestabilities of dry matter and organic matter and significantly increase energy digestibility (Tables 16 and 17). This was largely attributable to the significantly increased digestibility of total fatty acids (also reflected in increased ether extract digestibility). Ruminal L- carnitine tended to increase digestibilities of neutral detergent fiber (NDF) and cellulose. Ruminal L-carnitine also tended to increase total volatile fatty acid (VFA) concentration in the mmen, suggesting an enhancement of rumen fermentation (Table 18). L-Carnitine, especially into the mmen, tended to increase proportion of propionate and decrease proportion of acetate in ruminal contents.
TABLE 18
RUMINAL FERMENTATION CHARACTERISTICS FOR COWS
ADMINISTERED WITH L-CARNITINE INTO
THE RUMEN OR ABOMASUM
Item Treatments SEM Contrast (P)
Control Rumen Abomasu Control Rumen m vs. L- vs. carnitine Abomasu m pH 5.75 5.68 5.71 0.05 0.42 0.70
NH3, mg/dl 10.2 9.2 9.2 0.7 0.20 0.94
Total VFA, mM 120.2 125.5 120.2 1.9 0.29 0.09
VFA, mol/100 mol
Acetate 50.5 57.2 57.4 0.5 0.08 0.61
Propionate 29.7 30.4 29.8 0.4 0.05 0.35
Butyrate 10.0 9.7 10.0 0.3 0.84 0.48
Isovalerate 1.1 1.0 1.0 0.4 0.02 0.74
Valerate 1.7 1.6 1.7 0.05 0.30 0.57
Acetate: propionate 2.06 1.90 1.96 0.05 0.08 0.43
L-Carnitine tended to decrease concentration of nonesterified fatty acids
(NEFA) and increase ca itine concentration of glucose in blood plasma. Abomasal L- carnitine tended to decrease cholesterol in plasma (Table 19).
TABLE 19
CONCENTRATIONS OF METABOLITES IN PLASMA OF COWS ADMINISTERED WITH L-CARNITINE INTO THE RUMEN OR ABOMASUM
Item Treatment SEM Contrast (P)
Control Rum Abomasu Control vs. Rumen vs. en m L-carnitine abomasum
NEFA, μEq/ml 181.5 167.3 163.9 8.6 0.18 0.79
Cholesterol, mg/dl 224.4 224.6 210.0 4.7 0.27 0.07
Glucose, mg/dl 81.0 82.4 82.5 0.8 0.17 0.87
Urea N, mg/dl 14.8 13.4 13.7 0.6 0.16 0.73
Ruminal L-carnitine resulted in improvements in nitrogen retention and productive nitrogen, arising mostly from slightly improved nitrogen digestibility (Table
20). L-Carnitine resulted in increases in digestible and metabolizable energy from the diet, but this did not increase milk energy secretion, indicating that additional energy was directed was directed to body storage (Tables 21 and 22).
TABLE 20
NITROGEN UTILIZATION FOR COWS ADMINISTERED WITH L-CARNITINE IN THE RUMEN OR ABOMASUM
Item Treatments SEM Contrast (P)
Control Rumen Abomasum Control Rumen vs. L- vs. carnitine Abomasu m
N Intake, g/d 782 784 771 15 0.85 0.35
N excreted, g/d Feces' 285 260 274 9 0.14 0.32 Urine 228 228 227 10 0.99 0.93
Milk N, g/d 202 204 199 4 0.96 0.35
N absorbed, g/d 496 524 498 15 0.45 0.25
N retained, g/d 67 92 72 6 0.07 0.05
Productive N, g/d 268 296 271 8 0.17 0.06
N, % of Intake Feces 36.6 33.5 35.5 1.1 0.18 0.25 Urine 29.3 29.0 29.5 0.9 0.98 0.75 Milk2 25.9 26.3 25.7 0.3 0.76 0.15 Retained 8.2 11.2 9.3 0.7 0.06 0.11 Productive 34.2 37.5 35.0 0.9 0.09 0.09
N, % of absorbed Urine 46.5 43.7 45.7 1.1 0.23 0.23 Milk 40.8 39.7 40.1 0.8 0.40 0.71 Retained 12.7 16.6 14.1 1.2 0.11 0.18 Productive 53.6 56.3 54.3 1.1 0.23 0.23
'Carryover effect ^= .08 Direct effect means 263.7 247.4 307.9 0.49 0.85
Carryover effect p = Λ0 Direct effect means 25.8 27.1 24.8 0.72 0.82
TABLE 21
ENERGY UTILIZATION OF COWS ADMINISTERED WITH L-CARNITINE INTO THE RUMEN OF ABOMASUM
Item Treatments SEM Contrast (P)
Control Rumen Abomasum Control Rumen vs. L- vs. carnitin Abomas e um
(Mcal/d)
Intake energy 119.0 119.2 118.0 2.7 0.91 0.78
Fecal energy 45.4 42.7 43.3 0.9 0.08 0.65
Digestible energy 73.6 76.5 74.7 2.1 0.46 0.57
Urinary energy 4.2 4.4 4.7 0.2 0.19 0.41
Gaseous energy 5.6 5.8 5.6 0.2 0.76 0.56
Metabolizable 63.8 66.3 64.4 1.8 0.51 0.48 energy
Maintenance energy' 15.7 15.6 15.5 0.1 0.21 0.32
Metabolizable 48.1 50.7 48.9 1.7 0.47 0.49 energy above maintenance
Milk energy 29.1 28.8 28.3 0.3 0.18 0.33
Body weight2 577 574 570 3 0.22 0.32
'Carryover effect p= 0.01 Direct effect means 15.8 15.5 15.4 0.002 0.11
Carryover effect p= 0.01 Direct effect means 584 571 566 0.002 0.12
TABLE 22
ENERGY PARTITIONING IN COWS ADMINISTERED WITH L-CARNITINE INTO THE RUMEN OR ABOMASUM
Item Treatments SEM Contrast (P)
Control Rumen Abomasu Control Rumen m vs. L- vs. carnitine Abomas um
(% of gross energy intake)
Fecal energy 38.1 35.9 36.7 0.6 0.03 0.33
Urinary energy 3.5 3.7 4.0 0.2 0.13 0.17
Gaseous energy1 4.7 4.9 4.8 0.1 0.33 0.31
Metabolizable energy 53.6 55.6 54.5 0.4 0.03 0.14 (ME)
Metabolizable energy 40.4 42.3 41.3 0.6 0.11 0.29 above maintenace
Milk energy 24.7 24.5 24.0 6 0.64 0.60
Crude efficiency2-3 % 64.2 58.5 58.4 2.0 0.32 0.99
'Calculated from regression equation of Moe and Tyrrell (1979).
2Milk energy /ME above maintenance
Carryover effect p= 0.0497 Direct effect means 62.0 62.2 53.9 0.15 0.03
Claims
We claim: 1. A method for increasing the growth rate of mminants which comprises administering orally to the ruminant an effective amount of camitine.
2. The method of claim 1 wherein the camitine is combined with feed or water and said combination is fed to said ruminant.
3. The method of claim 1 wherein the ruminant is beef cattle, dairy cattle, swine or a ram.
4. The method of claim 1 wherein the camitine is L-carnitine or a salt thereof.
5. The method of claim 1 wherein the effective amount of ca itine is from about 125 mg per head per day to about 20 grams per head per day .
6. The method of claim 1 wherein said mminants are dairy cattle and the effective amount of ca itine is about 5 grams per head per day.
7. The method of claim 1 wherein said mminants are beef cattle and the effective amount of camitine is about 2 grams per head per day.
8. A method to facilitate the partitioning of milk components in a lactating ruminant which comprises administering orally to the ruminant an effective amount of camitine.
9. The method of claim 8 wherein the camitine is combined with feed or water and said combination is fed to said ruminant.
10. The method of claim 8 wherein the ruminant is dairy cattle or a goat.
11. The method of claim 8 wherein the camitine is L-carnitine.
12. The method of claim 8 wherein the effective amount of camitine is from about 125 mg per head per day to about 20 grams per head per day .
13. The method of claim 12 wherein said ruminants are dairy cattle and the effective amount of camitine is about 5 grams per head per day.
14. The method of claim 12 wherein said ruminants are beef cattle and the effective amount of camitine is about 2 grams per head per day.
15. A feed formulation for mminants comprising between 125 mg and 20 grams of camitine per head per day.
16. The formulation of claim 15 which is high in forage or roughage.
17. The formulation of claim 15 wherein the camitine is L-carnitine or a salt thereof.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19840594A | 1994-02-22 | 1994-02-22 | |
| US198405 | 1994-02-22 | ||
| PCT/US1995/002211 WO1995022259A1 (en) | 1994-02-22 | 1995-02-17 | Improving growth and lactation of ruminants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0746209A1 true EP0746209A1 (en) | 1996-12-11 |
Family
ID=22733244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP95911864A Withdrawn EP0746209A1 (en) | 1994-02-22 | 1995-02-17 | Improving growth and lactation of ruminants |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0746209A1 (en) |
| AU (1) | AU1927195A (en) |
| CA (1) | CA2183418A1 (en) |
| HU (1) | HUT75085A (en) |
| WO (1) | WO1995022259A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010084849A (en) * | 2000-02-29 | 2001-09-06 | 손 경 식 | Feedstuff for enriching L-carnitine in expressed milk of dairy cow |
| US6476010B2 (en) | 2000-03-10 | 2002-11-05 | Hill's Pet Nutrition | Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals |
| US20060159728A1 (en) * | 2005-01-14 | 2006-07-20 | Miller Bill L | Method of feeding milk replacer with carnitine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54129130A (en) * | 1978-03-27 | 1979-10-06 | Mitsubishi Chem Ind Ltd | Method for promoting roughage digestion of animal |
| JPH03246221A (en) * | 1981-01-26 | 1991-11-01 | Eiji Murakami | Rearing promoter |
| DE69019524T2 (en) * | 1989-07-31 | 1996-01-04 | Lonza Ag | CARNITE INDIA FOR FULL PIGS. |
| JPH05103596A (en) * | 1991-10-11 | 1993-04-27 | Yukio Yanagimoto | Enhancer for physical strength of land animal and feed for land animal |
-
1995
- 1995-02-17 AU AU19271/95A patent/AU1927195A/en not_active Abandoned
- 1995-02-17 WO PCT/US1995/002211 patent/WO1995022259A1/en not_active Ceased
- 1995-02-17 EP EP95911864A patent/EP0746209A1/en not_active Withdrawn
- 1995-02-17 CA CA002183418A patent/CA2183418A1/en not_active Abandoned
- 1995-02-17 HU HU9602279A patent/HUT75085A/en unknown
Non-Patent Citations (1)
| Title |
|---|
| See references of WO9522259A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| HUT75085A (en) | 1997-04-28 |
| HU9602279D0 (en) | 1996-10-28 |
| CA2183418A1 (en) | 1995-08-24 |
| AU1927195A (en) | 1995-09-04 |
| WO1995022259A1 (en) | 1995-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Blauwiekel et al. | Effect of crude protein and solubility on performance and blood constituents of dairy cows | |
| Palmquist et al. | Blood and hydrolyzed feather meals as sources of undegradable protein in high fat diets for cows in early lactation | |
| Casals et al. | Effects of calcium soaps and rumen undegradable protein on the milk production and composition of dairy ewes | |
| US6596300B1 (en) | Animal feed | |
| US20200260759A1 (en) | Diet formulations for ruminants | |
| Lee et al. | Responses to protein meal supplements by lactating beef cattle given a low-quality pasture hay | |
| CA2229560C (en) | Aliphatic amide feed supplement for ruminants | |
| US20040170669A1 (en) | Feed rations and methods of feeding growing ruminants | |
| Pritchard et al. | Effect of supplementation of wheat straw diets twice a day on rumen ammonia, volatile fatty acids and cow performance | |
| Owen et al. | Effect of molasses in normal-and high-grain rations on utilization of nutrients for lactation | |
| US4835185A (en) | Immunomodulator for improving commercial performance of domestic animals | |
| Chen et al. | Effects of dietary heat extruded soybean meal and protected fat supplement on the production, blood and ruminal characteristics of Holstein cows | |
| US4534969A (en) | Method for improving lactation in ruminant animals | |
| EP0746209A1 (en) | Improving growth and lactation of ruminants | |
| Chiou et al. | Studies on the application of an undegradable protein system to high yielding dairy cattle in Taiwan | |
| Huhtanen et al. | The effect of supplementation of grass silage with rapeseed meal or Gasol-treated barley on the performance of growing cattle | |
| Nilieh et al. | Interaction effect of starter physical form and alfalfa hay on growth performance, ruminal fermentation, and blood metabolites in Holstein calves | |
| Goodling et al. | Effects of postruminal protein on fatty acid digestibility in dairy cows | |
| Barman et al. | Cotton seed cake as protein supplement in buffalo calf ration | |
| Sarker et al. | Influence of feeding mustard oil cake and soybean meal in calf starter on growth and blood metabolites of crossbred dairy calves | |
| Erasmus et al. | Influence of different combinations of urea and low rumina! degradable protein sources on performance of high-producing dairy cows | |
| De Waal et al. | Supplementation of lactating Dorper and Merino ewes on Themeda cymbopogon veld. 3. Seasonal and diurnal variation in rumen pH and ammonia concentration | |
| US6525095B1 (en) | Propionate feed supplement | |
| Moss et al. | Effect of feather meal and blood meal supplementation on performance of dairy cattle | |
| Etman et al. | UTILIZATION FROM NEW NUTRITIONAL RESOURCES IN RUMENANT FEEDING: 1-EFFECT OF USING DRIED DISTILLERS GRAINS WITH SOLUBLES (DDGS) IN RATIONS FOR FATTENING FRIESIAN CALVES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19960829 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT CH DE ES FR GB IT LI |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19990901 |